Scoparia dulcis, commonly known as sweet broomweed or licorice weed, has a long history of use in traditional medicine systems, particularly in Asia, South America, and Africa, where it is employed for a variety of ailments including those related to blood sugar control. Its relevance to the "Pancreas Head body system" primarily stems from its traditional and emerging scientific use as a potential anti-diabetic plant.

Several preclinical studies have demonstrated that extracts of Scoparia dulcis can lower blood glucose levels in animal models. The plant contains several bioactive compounds, including scoparic acid, scoparicin, and flavonoids, which are thought to contribute to its hypoglycemic effects. For example, a number of studies (e.g., Pari & Latha, 2004; Oliveira et al., 2005) have shown that Scoparia dulcis extracts may enhance insulin secretion, promote pancreatic beta cell regeneration, and improve glucose tolerance in diabetic rats. These findings suggest a potential supportive effect on pancreatic function, particularly related to insulin production and secretion.

However, robust clinical trials in humans are lacking, and most evidence is limited to animal or in vitro studies. While the traditional use and preclinical evidence are promising, the overall scientific support for using Scoparia dulcis to directly support the pancreas in humans is moderate and warrants further research.